Abbott (Abbott Park, Illinois) reported a definitive agreement to acquire Evalve (Menlo Park, California), which makes devices for minimally invasive repair of cardiac mitral valves. The acquisition provides Abbott with a presence in the growing area of non-surgical treatment for structural heart disease. The agreement includes an upfront payment of $320 million in cash, plus an additional payment upon completion of certain regulatory milestones, for a total of up to $410 million. Last week Abbott agreed to acquire intraocular lens maker Visiogen (Irvine, California) for $400 million in cash. A more detailed story will be forthcoming in the Monday issue of Medical Device Daily.